Pharma-Bio Serv, Inc. (OTCQB:PBSV) reported increased revenue for the three and nine months ended July 31, 2026. The company recorded a quarterly net loss of $14 thousand and net income of approximately $252 thousand for the nine-month period.
#Revenue and earnings
Revenue for the three months ended July 31, 2026 was approximately $2.3 million, up approximately $0.4 million from the corresponding period of the prior year. Revenue for the nine months ended July 31, 2026 reached approximately $7.3 million, an increase of approximately $0.5 million compared with the same period last year.
Pharma-Bio Serv reported a net loss of $14 thousand for the three-month period. The company described this as an improvement of approximately $190 thousand compared with the corresponding period of the prior year.
For the nine months ended July 31, 2026, the company reported net income of approximately $252 thousand. This represented an improvement of approximately $352 thousand against the corresponding period of the prior year.
#Management comments
Victor Sanchez, Pharma-Bio Serv’s Chief Executive Officer, attributed the reported performance to client relationships, the company’s regulatory and compliance capabilities, a focus on selected markets and operating efficiencies. Sanchez also said management remained confident in its ability to build on the progress through the final quarter of the year.
The statement about the final quarter is forward-looking. The company said such statements are based on management’s expectations, estimates or projections as of the date of the earnings announcement and are subject to business, economic, competitive and other uncertainties that could cause actual results to differ materially.
#Business overview
Pharma-Bio Serv provides compliance, project management and technology transfer support consulting services. Its clients operate in the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries.
The company serves markets in Puerto Rico, the United States, Europe and Brazil. Its core business includes consulting related to compliance with requirements from the U.S. Food and Drug Administration and international agencies. Pharma-Bio Serv said its global team includes engineering and life science professionals, as well as quality assurance managers and directors.
#Forward-looking statement qualifications
Pharma-Bio Serv said the risks affecting its forward-looking statements include factors described in the risk factors section of its Annual Report on Form 10-K for the year ended October 31, 2025, along with factors in its other filings with the Securities and Exchange Commission.
The company stated that it disclaims any intention or obligation to update or revise forward-looking statements for subsequent events or circumstances, except where applicable law requires it.
#Key Takeaways
- Revenue was approximately $2.3 million for the three months ended July 31, 2026.
- Revenue for the nine months ended July 31, 2026 was approximately $7.3 million.
- The company reported a quarterly net loss of $14 thousand and nine-month net income of approximately $252 thousand.
- Pharma-Bio Serv provides regulatory compliance, project management and technology transfer support services across several industries and markets.
Original source: Read original article